A range of oral and nonoral triptans (e.g., sumatriptan) are available for the acute treatment of migraine and are entrenched in medical practice. However, triptans have noted clinical shortcomings in efficacy and adverse events that create opportunities for new and improved acute migraine drugs—three of which entered the U.S. market in H1 2020. These agents became the first migraine-specific acute therapies to be approved in nearly two decades. This report provides quantitative insight into neurologists’ perceptions of key treatment drivers and goals in the acute management of migraine and the current level of unmet need in this area. We analyze the commercial opportunities and how new / emerging compounds may capitalize on these opportunities.

QUESTIONS ANSWERED

  • What are the treatment drivers and goals in the management of acute migraine?
  • What drug attributes are key influences, which have limited impact, and which are hidden opportunities?
  • How do current therapies perform on key treatment drivers and goals?
  • What are the prevailing areas of unmet need and opportunity in the acute management of migraine?
  • What trade-offs across different clinical attributes and price are acceptable to U.S. and European neurologists for a hypothetical new drug for the acute treatment of migraine?

PRODUCT DESCRIPTION

Unmet Need provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, United Kingdom, France, Germany.

Primary research: Survey of 60 U.S. and 30 European neurologists fielded in August 2020.

Key drugs: Triptans (e.g., sumatriptan [multiple formulations]), DHE nasal spray, Reyvow, Ubrelvy, and Nurtec ODT.

Table of contents

  • Migraine - Unmet Need - Detailed, Expanded Analysis Acute Migraine

Author(s): Joyce Spadafora, ALM

Joyce is a business insights analyst in Decision Resources Group’s central nervous systems and ophthalmology division, where she provides expert insight into commercial aspects of drug development and market sizing across psychiatric and pain indications. She has worked extensively in DRG’s schizophrenia and chronic pain content.

Prior to joining DRG, Joyce spent several years in the biotech industry focused in research and development and in biotech consulting. Her project experience covered indications including psychiatry, pain, infectious diseases, respiratory, and ophthalmology. Beyond my therapeutic and industry knowledge, she holds a Masters in Extension Studies in Psychology from Harvard University and a B.S in Mechanical Engineering with Biology from the Massachusetts Institute of Technology.


Related Reports

Migraine - Geographic Focus: China - Migraine - China In-Depth (China)

Migraine presents a major public health burden in China, leading to impaired quality of life, widespread health loss, and loss of productivity for a sizeable population. Owing to migraine’s n...

View Details

Migraine - Landscape & Forecast - Disease Landscape & Forecast

The market for prescription migraine therapies comprises an array of prescription acute and prophylactic treatments and fosters a large and dynamic pipeline. In the acute space, we anticipate the l...

View Details

Migraine - Current Treatment - Detailed, Expanded Analysis (EU5)

According to DRG epidemiology, over 30 million people in the EU5 suffer migraines and over 10% of migraineurs suffer chronic migraine. Migraine prophylaxis is a core treatment approach for high-fre...

View Details

Migraine - Access & Reimbursement - Detailed, Expanded Analysis (US) - Acute Migraine

2020 will be a turning point for the U.S. acute migraine market. Three novel therapies—Allergan’s Ubrelvy, Eli Lilly’s Reyvow, and Biohaven’s Nurtec

View Details